Russia and Cuba create their first joint venture in biopharmaceutical sector

Cooperation in the pharmaceutical and biotechnology sectors has established itself as one of the main pillars of development for the BRICS countries.

In the case of India, the country is the world’s largest supplier of generic medicines, accounting for around 20 per cent of global supply and boasting an industry comprising more than 3,000 companies and 10,500 production plants. Furthermore, it leads the manufacture of vaccines such as those for diphtheria, tetanus and pertussis (DTP), Bacillus Calmette-Guerin (BCG) and measles, and supplies around 60 per cent of the doses procured by the United Nations Children’s Fund (UNICEF), according to an official report, as reported by IANS, a partner of TV BRICS.

Meanwhile, in China, researchers have developed an artificial intelligence-based platform capable of speeding up the assessment of interactions between drugs and proteins encoded in the human genome by up to a million times. According to CGTN, a partner of TV BRICS, the tool – used by more than a thousand researchers since its launch in 2025 – helps to speed up the discovery of new medicines and expand therapeutic options for diseases that still lack effective treatments.

Meanwhile, according to Mehr News Agency, a partner of TV BRICS, Iran is driving the development of nanotechnology-based medicines for the treatment of complex cancers and liver diseases. These therapies use nanocarriers that enable drugs to be targeted more precisely at the affected tissues, improving their efficacy and reducing side effects. Furthermore, the country has strengthened its domestic pharmaceutical production by developing alternatives that meet international quality standards.